These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23186833)

  • 1. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer.
    Zhao YZ; Dai DD; Lu CT; Chen LJ; Lin M; Shen XT; Li XK; Zhang M; Jiang X; Jin RR; Li X; Lv HF; Cai L; Huang PT
    Cancer Lett; 2013 Mar; 330(1):74-83. PubMed ID: 23186833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
    Lo YL; Liu Y; Tsai JC
    Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.
    Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR
    BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines.
    Azab SS; El-Demerdash E; Abdel-Naim AB; Youssef E; El-Sharkawy N; Osman AM
    Biochem Pharmacol; 2005 Sep; 70(5):725-32. PubMed ID: 16005435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
    Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
    Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals.
    Wu Y; Yang Y; Zhang FC; Wu C; Lü WL; Mei XG
    J Liposome Res; 2011 Sep; 21(3):221-8. PubMed ID: 20929434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid.
    Lo YL; Liu FI; Yang JM; Cherng JY
    Anticancer Res; 2001; 21(1A):445-50. PubMed ID: 11299776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of a Liposomal Formulation Incorporating an Antimicrobial Peptide from Tilapia as a New Adjuvant to Epirubicin in Human Squamous Cell Carcinoma and Pluripotent Testicular Embryonic Carcinoma Cells.
    Lo YL; Lee HP; Tu WC
    Int J Mol Sci; 2015 Sep; 16(9):22711-34. PubMed ID: 26393585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Liu X; Song Y; Deng Y
    Drug Deliv Transl Res; 2018 Jun; 8(3):602-616. PubMed ID: 29536348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
    Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
    J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations.
    Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S
    Int J Pharm; 2016 Mar; 501(1-2):18-31. PubMed ID: 26812610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
    Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.
    Yu Y; Wang ZH; Zhang L; Yao HJ; Zhang Y; Li RJ; Ju RJ; Wang XX; Zhou J; Li N; Lu WL
    Biomaterials; 2012 Feb; 33(6):1808-20. PubMed ID: 22136714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery.
    Chang LC; Wu SC; Tsai JW; Yu TJ; Tsai TR
    Int J Pharm; 2009 Jul; 376(1-2):195-203. PubMed ID: 19439169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells.
    Gyémánt N; Tanaka M; Antus S; Hohmann J; Csuka O; Mándoky L; Molnár J
    In Vivo; 2005; 19(2):367-74. PubMed ID: 15796199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals.
    Men Y; Wang XX; Li RJ; Zhang Y; Tian W; Yao HJ; Ju RJ; Ying X; Zhou J; Li N; Zhang L; Yu Y; Lu WL
    Int J Nanomedicine; 2011; 6():3125-37. PubMed ID: 22163164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells.
    Lo YL; Tu WC
    Chem Biol Interact; 2015 Dec; 242():13-23. PubMed ID: 26335193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells.
    Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X
    Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
    Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.